Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Lundin Gold Declares Quarterly Dividends of US$1.15 per Share

View original at finance.yahoo.com
Lundin Gold Declares Quarterly Dividends of US$1.15 per Share Lundin Gold logo (CNW Group/Lundin Gold Inc.) VANCOUVER, BC, Feb. 19, 2026 /CNW/ - Lundin Gold Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The variable dividend will be equal to an amount per share based on at least 50% of the Company's normalized free cash flow during the preceding quarter, less the fixed dividend paid during such period

    80% confidence

  • The company continues to demonstrate the quality of FDN and commitment to delivering meaningful returns to shareholders while advancing a growing pipeline of high value opportunities

    80% confidence

  • Lundin Gold's ability to consistently return capital to shareholders is driven by the exceptional margins and consistency of the Fruta del Norte asset

    80% confidence

  • Fruta del Norte is among the highest-grade operating gold mines in the world

    80% confidence

  • The quarterly dividend of US$1.15 per share reflects another period of strong performance and cash flow generation at Fruta del Norte and is based on returning 100% of normalized free cash flow, after payment of the fixed dividend, to shareholders

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Lundin Gold Declares Quarterly Dividends of US$1.15 per Share — Source | Via News | Finance Via News